Fibrocell to Present at Phacilitate Leaders World 2019

EXTON, Pa., Jan. 16, 2019 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced that John Maslowski, President and Chief Executive Officer, will present at Phacilitate Leaders World 2019 on Wednesday, January 23 at 2:05 pm EST in Miami, Florida. Mr. Maslowski will discuss FCX-007, the company’s gene therapy candidate for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), a devastating genetic skin disease with a high mortality rate. The presentation is part of the conference’s program focused on “Overcoming Obstacles In Vivo: The Road to Commercial Viability and Continuing Clinical Success in Viral Gene Therapy.”

About Fibrocell  

Fibrocell is an autologous cell and gene therapy company translating personalized biologics into medical breakthroughs for diseases affecting the skin and connective tissue.  Fibrocell's most advanced product candidate, FCX-007, is the subject of a Phase 1/2 clinical trial for the treatment of RDEB. Fibrocell is also developing FCX-013, the Company's clinical stage candidate for the treatment of moderate to severe localized scleroderma.  Fibrocell's gene therapy portfolio is being developed in collaboration with Intrexon Corporation (NASDAQ: XON), a leader in synthetic biology.  For more information, visit www.fibrocell.com or follow Fibrocell on Twitter at @Fibrocell.

Trademarks  

Fibrocell^®, the Fibrocell logo, and Fibrocell Science^® are trademarks of Fibrocell Science, Inc. and/or its affiliates.  All other names may be trademarks of their respective owners.

Investor & Media Relations Contact:
Karen Casey
484.713.6133
[email protected]

You May Also Be Interested In

• First Atlantic Nickel & Cobalt Announces Results of Annual General and Special Meeting
• Global Uranium Corp. Announces Conversion of Convertible Debentures
• Simply Good Foods Company Securities Fraud Class Action Result of Undisclosed Acquisition Failures and Over 27% Stock Decline - Investors May Contact Lewis Kahn, Esq., at Kahn Swick & Foti, LLC